COVID-19-Associated Guillain-Barre Syndrome: Atypical Para-infectious Profile, Symptom Overlap, and Increased Risk of Severe Neurological Complications
Abstract The concurrence of COVID-19 with Guillain-Barre syndrome (GBS) can increase the likelihood of neuromuscular respiratory failure, autonomic dysfunction, and other life-threatening symptoms. Currently, very little is known about the underlying mechanisms, clinical course, and prognostic implications of comorbid COVID-19 in patients with GBS. We reviewed COVID-19-associated GBS case reports published since the outbreak of the pandemic, with a database search up to August 2020, including a manual search of the reference lists for additional relevant cases. Fifty-one (51) case reports of COVID-19 patients (aged 23–84 years) diagnosed with GBS in 11 different countries were included in this review. The results revealed atypical manifestations of GBS, including para-infectious profiles and onset of GBS without antecedent COVID-19 symptoms. Although all tested patients had signs of neuroinflammation, none had SARS-CoV-2 in the cerebrospinal fluid (CSF), and only four (4) patients had antiganglioside antibodies. The majority had a 1- to 10-day time interval between the onset of COVID-19 and GBS symptoms, and many had a poor outcome, with 20 out of the 51 (39.2%) requiring mechanical ventilation, and two deaths within 12 to 24 h. The atypical manifestations of COVID-19-associated GBS, especially the para-infectious profile and short time interval between the onset of the COVID-19 and GBS symptoms, increase the likelihood of symptom overlap, which can complicate the treatment and result in worsened disease progression and/or higher mortality rates. Inclusion of a neurological assessment during diagnosis of COVID-19 might facilitate timely identification and effective management of the GBS symptoms and improve treatment outcome..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:2 |
---|---|
Enthalten in: |
SN comprehensive clinical medicine - 2(2020), 12 vom: 21. Nov., Seite 2702-2714 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Kajumba, Mayanja M. [VerfasserIn] |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
Themen: |
Atypical |
---|
doi: |
10.1007/s42399-020-00646-w |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
SPR04231142X |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | SPR04231142X | ||
003 | DE-627 | ||
005 | 20230520004910.0 | ||
007 | cr uuu---uuuuu | ||
008 | 201210s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s42399-020-00646-w |2 doi | |
035 | |a (DE-627)SPR04231142X | ||
035 | |a (DE-599)SPRs42399-020-00646-w-e | ||
035 | |a (SPR)s42399-020-00646-w-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |q ASE |
082 | 0 | 4 | |a 610 |q ASE |
100 | 1 | |a Kajumba, Mayanja M. |e verfasserin |4 aut | |
245 | 1 | 0 | |a COVID-19-Associated Guillain-Barre Syndrome: Atypical Para-infectious Profile, Symptom Overlap, and Increased Risk of Severe Neurological Complications |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Abstract The concurrence of COVID-19 with Guillain-Barre syndrome (GBS) can increase the likelihood of neuromuscular respiratory failure, autonomic dysfunction, and other life-threatening symptoms. Currently, very little is known about the underlying mechanisms, clinical course, and prognostic implications of comorbid COVID-19 in patients with GBS. We reviewed COVID-19-associated GBS case reports published since the outbreak of the pandemic, with a database search up to August 2020, including a manual search of the reference lists for additional relevant cases. Fifty-one (51) case reports of COVID-19 patients (aged 23–84 years) diagnosed with GBS in 11 different countries were included in this review. The results revealed atypical manifestations of GBS, including para-infectious profiles and onset of GBS without antecedent COVID-19 symptoms. Although all tested patients had signs of neuroinflammation, none had SARS-CoV-2 in the cerebrospinal fluid (CSF), and only four (4) patients had antiganglioside antibodies. The majority had a 1- to 10-day time interval between the onset of COVID-19 and GBS symptoms, and many had a poor outcome, with 20 out of the 51 (39.2%) requiring mechanical ventilation, and two deaths within 12 to 24 h. The atypical manifestations of COVID-19-associated GBS, especially the para-infectious profile and short time interval between the onset of the COVID-19 and GBS symptoms, increase the likelihood of symptom overlap, which can complicate the treatment and result in worsened disease progression and/or higher mortality rates. Inclusion of a neurological assessment during diagnosis of COVID-19 might facilitate timely identification and effective management of the GBS symptoms and improve treatment outcome. | ||
650 | 4 | |a SARS-CoV-2 |7 (dpeaa)DE-He213 | |
650 | 4 | |a COVID-19 |7 (dpeaa)DE-He213 | |
650 | 4 | |a Atypical |7 (dpeaa)DE-He213 | |
650 | 4 | |a Guillain-Barre |7 (dpeaa)DE-He213 | |
650 | 4 | |a Para-infectious |7 (dpeaa)DE-He213 | |
650 | 4 | |a Prognosis |7 (dpeaa)DE-He213 | |
700 | 1 | |a Kolls, Brad J. |e verfasserin |4 aut | |
700 | 1 | |a Koltai, Deborah C. |e verfasserin |4 aut | |
700 | 1 | |a Kaddumukasa, Mark |e verfasserin |4 aut | |
700 | 1 | |a Kaddumukasa, Martin |e verfasserin |4 aut | |
700 | 1 | |a Laskowitz, Daniel T. |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t SN comprehensive clinical medicine |d [Cham] : Springer International Publishing, 2019 |g 2(2020), 12 vom: 21. Nov., Seite 2702-2714 |w (DE-627)SPR038535785 |w (DE-600)2947252-0 |x 2523-8973 |7 nnns |
773 | 1 | 8 | |g volume:2 |g year:2020 |g number:12 |g day:21 |g month:11 |g pages:2702-2714 |
856 | 4 | 0 | |u https://dx.doi.org/10.1007/s42399-020-00646-w |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_SPRINGER | ||
912 | |a SSG-OLC-PHA | ||
951 | |a AR | ||
952 | |d 2 |j 2020 |e 12 |b 21 |c 11 |h 2702-2714 |